N4 Pharma Plc announced that it has engaged Melody Janssen PhD under a consultancy contract to lead its internal and external research program for its novel delivery system, Nuvec®. In conjunction with Melody's appointment, Andrew Leishman will step down as Head of the Nuvec® division with effect from 10 January 2019, to enable him to take up other consultancy positions. Thereafter, he will continue to work with and advise the Company as a consultant. Melody has extensive experience of different delivery systems and was formerly Head of R&D and pre-clinical development for Mymetics.